文献速递贫血与红细胞疾病

培西他普治疗冷凝集素病与温抗体型自身免疫性溶血性贫血的安全性和疗效

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
PubMed 文献 · Blood · 2025-01-01

这项开放标签2期研究在冷凝集素病(CAD)与温抗体型自身免疫性溶血性贫血(wAIHA)两个队列中,将患者随机分配接受培西他普270 mg/d或360 mg/d治疗最多48周;CAD队列13/13(100%)、wAIHA队列10/11(91%)患者出现至少1例治疗中出现的不良事件,未出现被认为与培西他普相关的严重不良事件,培西他普可升高血红蛋白、减轻溶血并改善疲劳评分。

要点

  • CAD队列13/13(100%)、wAIHA队列10/11(91%)患者出现至少1例治疗中出现的不良事件。
  • 10例患者出现至少1例严重不良事件,均未被认为与培西他普相关。
  • 第48周CAD总组血红蛋白较基线中位变化2.4 g/dL,wAIHA总组为1.7 g/dL。

核心结论

  • 本研究表明培西他普总体耐受性良好,并提示其对CAD和wAIHA患者可能有效。

研究设计与样本

  • 开放标签2期研究,设CAD与wAIHA两个队列,每队列患者随机接受培西他普270 mg/d或360 mg/d,治疗最多48周。

主要发现

  • CAD队列13/13(100%)、wAIHA队列10/11(91%)患者出现至少1例治疗中出现的不良事件。
  • 10例患者出现至少1例严重不良事件,均未被认为与培西他普相关。
  • 唯一与治疗相关的不良事件特别关注为注射部位反应。
  • 培西他普在最初数周内升高血红蛋白、减轻溶血并提高FACIT-疲劳量表评分。
  • 第48周CAD总组血红蛋白较基线中位(四分位距)变化为2.4(0.90-3.00)g/dL,wAIHA总组为1.7(-1.40至2.90)g/dL,溶血改善与FACIT-疲劳量表评分改善得以维持。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) are rare autoimmune hemolytic anemias characterized by red blood cell destruction, largely attributable to complement activation resulting in intravascular and extravascular hemolysis. Pegcetacoplan is a subcutaneously administered C3-targeted therapy, which may be suitable for treating CAD and wAIHA. In this open-label phase 2 study, analyses were conducted in 2 cohorts, 1 for patients with CAD and the other for those with wAIHA. In each cohort, patients were randomly assigned to receive pegcetacoplan 270 mg/d or 360 mg/d for up to 48 weeks. Safety end points included the incidence and severity of treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI). Efficacy end points included change from baseline in hemoglobin (Hb), lactate dehydrogenase, absolute reticulocyte count, haptoglobin, indirect bilirubin, and functional assessment of chronic illness therapy (FACIT)-fatigue scale. Thirteen of 13 (100%) and 10 of 11 (91%) patients with CAD and wAIHA, respectively, experienced at least 1 TEAE. Ten patients had at least 1 serious AE; none were considered related to pegcetacoplan. The only treatment-related AESIs were injection site reactions. Pegcetacoplan increased Hb levels, reduced hemolysis, and increased FACIT-fatigue scale scores in the first weeks; at week 48 the median (interquartile range) change from baseline Hb for the CAD and wAIHA total groups was 2.4 (0.90-3.00) and 1.7 g/dL (-1.40 to 2.90), respectively, and improvements in hemolysis and FACIT-fatigue scale scores were maintained. This study demonstrated that pegcetacoplan is generally well tolerated and suggests it can be effective for patients with CAD and wAIHA. This trial was registered at www.ClinicalTrials.gov as #NCT03226678.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Roman E, Fattizzo B, Shum M, et al. Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia. Blood. 2025. PMID: 39486046. doi:10.1182/blood.2023022549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。